Goldman Sachs’s BioNTech BNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-52,100
Closed -$4.96M 6498
2025
Q4
$4.96M Hold
52,100
﹤0.01% 3754
2025
Q3
$5.14M Hold
52,100
﹤0.01% 3621
2025
Q2
$5.55M Hold
52,100
﹤0.01% 3316
2025
Q1
$4.74M Hold
52,100
﹤0.01% 3408
2024
Q4
$5.94M Hold
52,100
﹤0.01% 3284
2024
Q3
$6.19M Buy
52,100
+35,200
+208% +$3.24M ﹤0.01% 3160
2024
Q2
$1.36M Buy
16,900
+5,100
+43% +$466K ﹤0.01% 4240
2024
Q1
$1.09M Buy
+11,800
New +$1.13M ﹤0.01% 4287
2023
Q4
Sell
-15,400
Closed -$1.67M 5633
2023
Q3
$1.67M Buy
+15,400
New +$1.7M ﹤0.01% 3906
2023
Q1
Sell
-112,300
Closed -$16.9M 5929
2022
Q4
$16.9M Buy
112,300
+44,600
+66% +$6.86M ﹤0.01% 2112
2022
Q3
$9.13M Buy
67,700
+37,700
+126% +$5.76M ﹤0.01% 2595
2022
Q2
$4.47M Sell
30,000
-44,800
-60% -$6.84M ﹤0.01% 3239
2022
Q1
$12.8M Sell
74,800
-156,200
-68% -$26.2M ﹤0.01% 2449
2021
Q4
$59.6M Buy
231,000
+111,000
+93% +$30.4M 0.01% 1205
2021
Q3
$32.8M Buy
120,000
+30,500
+34% +$9.69M 0.01% 1622
2021
Q2
$20M Buy
89,500
+39,500
+79% +$7.45M ﹤0.01% 2046
2021
Q1
$5.46M Buy
+50,000
New +$5.31M ﹤0.01% 3059

Other funds holding BNTX

Goldman Sachs's BNTX Position: Q1 2026 in Review

Goldman Sachs reduced its BioNTech (BNTX) stake by 11% in Q1 2026, selling an estimated $1.17M and leaving 96,829 shares worth $8.61M. The position accounts for ﹤0.01% of the portfolio, ranked #3191.

Goldman Sachs first reported a position in BNTX in Q2 2020 and has held it in 24 quarters since. The position peaked at $84.7M in Q4 2021. 272 funds tracked by Wall St. Rank hold BNTX as of Q1 2026.

  • Goldman Sachs held 96,829 shares of BioNTech worth $8.61M as of Q1 2026.
  • Goldman Sachs sold 11,417 BioNTech shares in Q1 2026, an estimated $1.17M.
  • BioNTech made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3191 holding.
  • Goldman Sachs first reported a position in BioNTech in Q2 2020 and has held it in 24 quarters since.
  • Goldman Sachs's BioNTech position peaked at $84.7M in Q4 2021.
  • 272 funds tracked by Wall St. Rank held BioNTech as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.